LC
VKTX icon

Luminist Capital’s Viking Therapeutics VKTX Stock Holding History

Luminist Capital’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-250
Closed -$8.79K – 278
2025
Q4 		$8.79K Buy
250
+150
+150% +$5.32K 0.01% 147
2025
Q3 		$2.74K Buy
+100
New +$2.98K ﹤0.01% 263

Other funds holding VKTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Luminist Capital's VKTX Position: Q1 2026 in Review

Luminist Capital sold out of Viking Therapeutics (VKTX) in Q1 2026, closing a stake of 250 shares — an estimated $8.79K sold.

Luminist Capital first reported a position in VKTX in Q3 2025 and held it in 2 quarters. The position peaked at $8.79K in Q4 2025. 410 funds tracked by Wall St. Rank hold VKTX as of Q1 2026.

  • Luminist Capital reported no remaining Viking Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Luminist Capital sold 250 Viking Therapeutics shares in Q1 2026, an estimated $8.79K.
  • Luminist Capital first reported a position in Viking Therapeutics in Q3 2025 and held it in 2 quarters.
  • Luminist Capital's Viking Therapeutics position peaked at $8.79K in Q4 2025.
  • 410 funds tracked by Wall St. Rank held Viking Therapeutics as of Q1 2026.

Based on Luminist Capital's 13F filing for Q1 2026, filed 24 Apr 2026.